US Stock Market Move | Q3 results beat expectations and full-year guidance was raised; Merck & Co., Inc. (MRK.US) rose more than 5% after earnings.

On Thursday, Merck & Co., Inc. (MRK.US) opened higher and climbed, rising more than 5% as of press time, with a market capitalization of US$365.8 billion. On the news front, Merck & Co., Inc. reported third-quarter 2026 results, with revenue growth driven by products including its cancer drug Keytruda and pulmonary arterial hypertension drug WINREVAIR. Q3 total revenue was US$18.085 billion, up 5% year over year (4% excluding the impact of foreign exchange), above the average analyst estimate of US$17.31 billion compiled by LSEG; adjusted earnings per share were US$2.49, far exceeding the expected US$2.08; net income under GAAP was US$5.065 billion, with earnings per share of US$2.04, both down 12% year over year. The company also raised its full-year guidance the same day: the low end of its 2026 revenue range was lifted from US$66.3 billion to US$66.8 billion, and full-year adjusted earnings per share guidance was raised from US$2.662.76 to US$2.772.82.